申请人:KOURA Minoru
公开号:US20100016327A1
公开(公告)日:2010-01-21
[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.
[Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.
提供一种新型的LXRβ激动剂,可用作预防和/或治疗动脉粥样硬化;动脉硬化,如糖尿病引起的动脉硬化;血脂异常;高胆固醇血症;与脂质相关的疾病;由炎症性细胞因子引起的炎症性疾病;过敏性皮肤病;糖尿病;或阿尔茨海默病的治疗剂。通过以下一般式(1)表示的喹啉化合物或其盐,或它们的溶剂化合物。